Major healthcare companies like BMS, J&J, and EL are facing market pressures, including biosimilar erosion, while maintaining strong sector positions.
1 report, 1 independent
Updated Aug 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Major healthcare companies like BMS, J&J, and EL are facing market pressures, including biosimilar erosion, while maintaining strong sector positions.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.Sub-event
Industry snapshot covering stock performance, XLV holdings, and biosimilar erosion.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- Biosimilar erosion is impacting market share, and AbbVie, Procter & Gamble, and Johnson & Johnson are noted as major consumer goods players.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- Nvidia, Eli Lilly, and Booking Holdings are high-growth stocks attracting investor attention, with Eli Lilly being specifically compared to Booking Holdings' stock split.
- Johnson & Johnson and Recordati Industria Chimica E Farmaceutica are noted as large-cap healthcare companies.